Payment overview · 2025
General Payments
$2,062.02
101 reported records · 18 companies
Healthcare provider profile · identity verified
Thomas Joseph Raimondo, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · WARWICK, RI · NPI 1245236918
Verified facts
What the public records show
CMS Open Payments records show Thomas Joseph Raimondo, DO received $2,062.02 in general payments during 2025 across 101 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 588 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $485.15 | 23.5% | 24 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $344.60 | 16.7% | 19 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $237.33 | 11.5% | 10 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $155.34 | 7.5% | 8 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $128.96 | 6.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $107.05 | 5.2% | 6 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $105.20 | 5.1% | 4 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $90.92 | 4.4% | 4 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $87.98 | 4.3% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $75.56 | 3.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.62 | 2.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.45 | 2.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $36.98 | 1.8% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $24.21 | 1.2% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $19.86 | 1.0% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $19.45 | 0.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.21 | 0.9% | 1 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $16.15 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,062.02 | 101 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $366.29 | 16 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $326.71 | 15 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $210.04 | 12 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $155.34 | 8 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $134.56 | 7 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $109.15 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $89.26 | 5 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $87.98 | 4 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $79.40 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $75.56 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $55.82 | 3 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.45 | 3 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $25.80 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 588 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
588 | 99 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 653 | 153 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 588 | 99 |
| Prednisone | Prednisone | 348 | 129 |
| Azithromycin | Azithromycin | 347 | 86 |
| Montelukast Sodium | Montelukast Sodium | 346 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 280 | 78 |
| Breo Ellipta | Fluticasone/Vilanterol | 253 | 40 |
| Omeprazole | Omeprazole | 220 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 61 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 145 | 28 |
| Arnuity Ellipta | Fluticasone Furoate | 138 | 25 |
| Furosemide | Furosemide | 138 | 35 |
| Ventolin Hfa | Albuterol Sulfate | 135 | 41 |
| Cefuroxime | Cefuroxime Axetil | 134 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 132 | 29 |
| Gabapentin | Gabapentin | 122 | 18 |
| Trazodone Hcl | Trazodone Hcl | 119 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 113 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 112 | 23 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 109 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 102 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 22 |
| Incruse Ellipta | Umeclidinium Bromide | 96 | 20 |
| Spiriva Respimat | Tiotropium Bromide | 93 | 18 |
| Sertraline Hcl | Sertraline Hcl | 88 | 20 |
| Losartan Potassium | Losartan Potassium | 84 | 21 |
| Roflumilast | Roflumilast | 84 | 11 |
| Potassium Chloride | Potassium Chloride | 82 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 82 | 23 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 79 | 16 |
| Cefprozil | Cefprozil | 77 | 52 |
| Theophylline Er | Theophylline Anhydrous | 74 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 71 | 17 |
| Famotidine | Famotidine | 70 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 66 | 17 |
| Lisinopril | Lisinopril | 62 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 60 | 14 |
| Alendronate Sodium | Alendronate Sodium | 59 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 55 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Methylprednisolone | Methylprednisolone | 53 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 31 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 12 |
| Metformin Hcl | Metformin Hcl | 48 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 47 | 16 |
| Eliquis | Apixaban | 46 | 11 |
| Meloxicam | Meloxicam | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 19 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Dulera | Mometasone/Formoterol | 25 | suppressed |
| Dupixent Pen | Dupilumab | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Nystatin | Nystatin | 23 | 14 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Carvedilol | Carvedilol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Zafirlukast | Zafirlukast | 15 | suppressed |
| Bosentan | Bosentan | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dupixent Syringe | Dupilumab | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Pirfenidone | Pirfenidone | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,062.02 · 101 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, CUTAQUIG, DUPIXENT, FASENRA, Hizentra, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, OPSUMIT, OPSYNVI, Ohtuvayre, PANZYGA, PAXLOVID, Prolastin-C Liquid, RUCONEST, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, YUPELRI, ZERBAXA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error